European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1 The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2 The new liquid formulation of infliximab, available in … [Read more…]

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed … [Read more…]

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg

 Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence INCHEON, South Korea–(BUSINESS WIRE)–The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s … [Read more…]

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Halda Therapeutics acquired by Johnson & Johnson for $3.05 billion – the largest acquisition ever across any therapeutic area for a Phase 1 company Scorpion Therapeutics acquired by Eli Lilly for Up to $2.5 billion – one of the highest-value strategic transactions announced in early 2025 Vigil Neuroscience acquired by Sanofi for a $470 million … [Read more…]

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to File an Investigational New Drug Application in Q1 2026 Reported Positive Topline … [Read more…]

LuskinOIC Awarded $1 Million Grant from the Everychild Foundation to Fund the Institute’s First MRI Unit

Landmark gift completes $2.1M campaign, making LuskinOIC the only pediatric facility in downtown Los Angeles with on-site MRI LOS ANGELES–(BUSINESS WIRE)–#CommunityImpact–The Everychild Foundation has awarded Luskin Orthopaedic Institute for Children (LuskinOIC) a transformative $1 million grant to purchase the Institute’s first MRI unit—marking the first seven-figure foundation grant in the nonprofit’s 114-year history. This extraordinary … [Read more…]

Unite Us Names Sean Burke President to Build on National Momentum and Impact

Experienced healthcare executive brings deep leadership expertise advancing technology solutions that improve healthcare access and outcomes by uniting people, systems, and purpose. NEW YORK–(BUSINESS WIRE)–Unite Us, the nation’s trusted technology partner for integrating health and community-based care, today announced the appointment of Sean Burke as its new President. With a career dedicated to improving healthcare … [Read more…]

GE HealthCare announces Flyrcado milestone: Strong pilot results drive broader rollout at CVAUSA

CVAUSA, the largest network of private cardiology groups in the U.S., plans to broadly adopt Flyrcado in line with its mission to deliver the highest quality cardiovascular care for patients. CVAUSA currently performs approximately 85,000 cardiac positron emission tomography (PET) procedures annually, highlighting the potential opportunity for Flyrcado as adoption grows. GE HealthCare remains committed … [Read more…]

Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation

LONDON & MUMBAI, India–(BUSINESS WIRE)–$LTIM #AI—LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced its selection as a strategic partner by Convatec, a leading global medical products and technologies company, for the implementation of SAP’s Digital Core – S/4HANA. As part of this engagement, LTIMindtree will support Convatec to … [Read more…]

Deciphera Announces the Opening of a New Office in Zug, Switzerland

– New 733-square-meter office will allow Deciphera to strategically expand its operations and further advance its commercial reach in Europe – OSAKA, Japan & WALTHAM, Mass.–(BUSINESS WIRE)–Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the opening of a new 733-square-meter office in Zug, Switzerland, to accommodate the company’s … [Read more…]